PURPOSE: To report the external ocular changes in 2 patients receiving epidermal growth factor receptor (EGFR) inhibitors. METHODS: Retrospective observational case series. Two patients receiving epidermal growth factor inhibitors for metastatic non-small-cell lung carcinoma were followed clinically and with external photographs. RESULTS: Findings included acneiform facial changes, telangiectasia of eyelid margins, meibomitis, tear film dysfunction, and unusual, hyperpigmented, tortuous eyelashes. CONCLUSIONS: EGFR inhibitors used in the treatment of certain malignancies can lead to symptomatic adnexal and ocular surface changes. Ophthalmologists should be aware of these to appropriately manage them.
PURPOSE: To report the external ocular changes in 2 patients receiving epidermal growth factor receptor (EGFR) inhibitors. METHODS: Retrospective observational case series. Two patients receiving epidermal growth factor inhibitors for metastatic non-small-cell lung carcinoma were followed clinically and with external photographs. RESULTS: Findings included acneiform facial changes, telangiectasia of eyelid margins, meibomitis, tear film dysfunction, and unusual, hyperpigmented, tortuous eyelashes. CONCLUSIONS:EGFR inhibitors used in the treatment of certain malignancies can lead to symptomatic adnexal and ocular surface changes. Ophthalmologists should be aware of these to appropriately manage them.
Authors: Rebecca Kaye; Nora Botten; Marit Lippestad; Dayu Li; Robin R Hodges; Tor P Utheim; Charles N Serhan; Darlene A Dartt Journal: Exp Eye Res Date: 2018-12-01 Impact factor: 3.467